Provided by Tiger Fintech (Singapore) Pte. Ltd.

InMed Pharmaceuticals Inc

2.88
+0.14005.11%
Pre-market: 2.850.0700+2.52%08:00 EDT
Volume:21.91K
Turnover:61.32K
Market Cap:3.48M
PE:-0.21
High:2.88
Open:2.72
Low:2.65
Close:2.74
Loading ...

InMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)

Simply Wall St.
·
14 Feb

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Newsfile
·
13 Feb

InMed Advances INM-089 for Dry AMD Treatment with New Intravitreal Formulation

TIPRANKS
·
03 Feb

InMed Pharmaceuticals announces INM-089 IVT formulation as drug candidate

TIPRANKS
·
03 Feb

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Newsfile
·
03 Feb

InMed Pharmaceuticals granted an international PCT patent

TIPRANKS
·
22 Jan

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Newsfile
·
22 Jan

InMed Shares Rise, Study Indicates Alzheimer's Drug Could Lower Neuroinflammation

Dow Jones
·
22 Jan

BRIEF-InMed’S INM-901 Demonstrates Statistically Significant Reduction In Neuroinflammation In Long-Term Preclinical Alzheimer’S Disease Study

Reuters
·
22 Jan

InMed’s Inm-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer’s Disease Study

THOMSON REUTERS
·
21 Jan

Dow Jumps 200 Points; 3M Posts Upbeat Q4 Results

Benzinga
·
21 Jan

InMed Pharmaceuticals Says Alzheimer's Disease Trial Shows Significant Reduction in Neuroinflammation

MT Newswires Live
·
21 Jan

InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study

TIPRANKS
·
21 Jan

InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study

TIPRANKS
·
21 Jan

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Newsfile
·
21 Jan

InMed Pharmaceuticals files to sell 3M common shares for holders

TIPRANKS
·
24 Dec 2024